Buy Zepbound (Tirzepatide) — Online Prescription

With no insurance or with a plan that excludes weight-loss drugs, the cheapest route is Lilly's self-pay pricing: $299 for the 2.5 mg starter month, $399 for 5 mg and $449 a month for 7.5 to 15 mg, on either the KwikPen or vials. The KwikPen price is available through LillyDirect and, with Lilly's KwikPen Self-Pay Savings Card, at retail pharmacies. Vials at 7.5 mg and up cost $599 to $1,049 if you refill more than 45 days after the previous delivery. (Arrow Pharmacy can't process the KwikPen self-pay card. For that route, use LillyDirect.) Four single-dose pens with no program run more than $1,000 a month.

There are two cards. The standard Savings Card is for people with commercial insurance. If your plan covers Zepbound, you pay as little as $25 for a 1-, 2- or 3-month fill, but the card takes off at most $100 per month and $1,300 per calendar year, so $25 only works if your normal copay is about $125 or less. If your commercial plan does not cover Zepbound, the card brings single-dose pens down to as low as $499 a month. The separate KwikPen Self-Pay Savings Card is open to everyone, including the uninsured, and gives the $299–$449 self-pay prices at the pharmacy. Neither card can be used with Medicare, Medicaid or other government insurance. The current cards expire December 31, 2026.

For weight loss, through a new route. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge lets eligible Part D members get the Zepbound KwikPen (not vials or single-dose pens), Wegovy or Foundayo for $50 a month. You generally need a BMI of 35 or more, or 27 or more with certain weight-related conditions, and you must not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, which are handled through regular Part D coverage instead. People who already got a GLP-1 through their Part D plan in 2026 stay on that coverage. Part D plans may also cover Zepbound for sleep apnea under their normal rules.

Same medicine, different approvals. Both are tirzepatide from Eli Lilly at the same doses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight reduction and long-term weight maintenance, and for obstructive sleep apnea with obesity. Insurance treats them as separate products: a plan may cover Mounjaro for diabetes and still exclude Zepbound for weight loss. They should never be used together.

No. Tirzepatide is still under patent and there is no FDA-approved generic. Products sold online as "generic Zepbound" or "tirzepatide" are compounded or research-chemical products, not an approved generic. The FDA declared the tirzepatide shortage over in December 2024, which ended the temporary allowance for mass compounding of copies.

Not Zepbound itself. Lilly's oral weight-loss pill is Foundayo (orforglipron), a different molecule that the FDA approved in 2026. It is a daily tablet taken without food or water restrictions, with self-pay prices starting at $149 a month. It is not tirzepatide in pill form.

In the main 72-week FDA trial, average weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% on placebo. More than half of people on 10 mg or 15 mg lost at least 20% of their body weight. In a head-to-head trial (SURMOUNT-5), tirzepatide averaged 20.2% weight loss versus 13.7% for semaglutide (Wegovy).

Most people regain weight. In the FDA withdrawal study, people who switched to placebo after 36 weeks regained an average of 14% of their body weight over the next year, while those who stayed on Zepbound lost a further 5.5%. Zepbound is approved for long-term weight maintenance, and most people need to continue it to keep the benefit.

Start with 2.5 mg once a week for 4 weeks, then 5 mg. If needed, the dose goes up by 2.5 mg at a time, at least 4 weeks apart, to a maximum of 15 mg. Maintenance doses for weight are 5, 10 or 15 mg; for sleep apnea, 10 or 15 mg. The 2.5 mg dose is only for starting. If you miss a dose, take it within 4 days; after that, skip it and take the next dose on schedule.

Stomach and gut effects, mostly while doses are increasing: nausea (25–29% of people vs. 8% on placebo), diarrhea (19–23%), vomiting (8–13%) and constipation (11–17%). Others include stomach pain, indigestion, injection-site reactions, fatigue, burping and hair loss (4–5% vs. 1%). In the trials, 4.8–6.7% of people stopped because of side effects, compared with 3.4% on placebo.

Yes. Because tirzepatide slows stomach emptying, it can reduce how well birth control pills are absorbed. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting Zepbound and for 4 weeks after each dose increase. IUDs, implants, injections, patches and rings are not affected.

Single-dose pens and single-dose vials can be kept unrefrigerated, up to 86°F, for a total of 21 days. Once a KwikPen or multi-dose vial is in use, it can be kept in the fridge or at room temperature (up to 86°F), but must be thrown away after 30 days or after its 4 weekly doses, whichever comes first. Never freeze it, and keep it in the carton to protect it from light.

You can get a legitimate online prescription from a licensed telehealth provider and fill it at a US pharmacy such as Arrow Pharmacy, or through LillyDirect's home delivery. Websites that sell tirzepatide without a prescription, or "research peptides" labeled not for human use, are not legitimate sources.

It depends on how you pay. Both makers now offer self-pay prices in a similar range, and Medicare's $50 Bridge covers both. With commercial insurance, the deciding factor is which one your plan puts on its formulary. Ask us to check both against your plan before your prescriber writes the prescription.